Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018799 (heart disease)
 34,133 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Prerequisite of a rational antiarrhythmic therapy is the correct diagnosis of the given cardiac rhythm disorder. The majority of intermittent and latent cardiac arrhythmias can be reliably induced and analyzed during the electrophysiologic study (EPS). In case of bradyarrhythmias, the method is indicated in patients with suspected sinus node disease or high-grade AV conduction disturbances, as far as the cause of clinical symptoms cannot be settled by Holter recordings. Since patients with paroxysmal supraventricular tachycardias (WPW syndrome and AV nodal reentrant tachycardia) can be cured by transvenous ablation techniques, EPS is indicating in this setting in all symptomatic patients for the diagnosis and the treatment of the given arrhythmia. In patients with recurrent ventricular tachyarrhythmias, EPS should be performed to establish the diagnosis and to control medical treatment; in addition, EPS is a prerequisite for nonpharmacologic treatment modalities such as defibrillator therapy and transvenous or surgical ablation techniques. In survivors of cardiac arrest without new Q-wave myocardial infarction, persistent ventricular tachyarrhythmias can be induced in some 50% of the patients. Patients should be evaluated by EPS in case the reasons for significant clinical symptoms cannot be determined otherwise, given the likelihood, that brady- or tachyarrhythmias are the cause of the clinical symptoms; this includes patients with organic heart disease and with unexplained syncopes.
 ...
PMID:[Who should be referred for electrophysiologic studies?]. 151 85

Since the first successful surgical intervention for Wolff-Parkinson-White syndrome by W. C. Sealy, a surgical electrophysiological intervention has been developed for every single supraventricular arrhythmia. The surgical rationale is based on the site of the mechanism of the arrhythmia and associated pathology which characterizes the "arrhythmogenic substrate". Wolff-Parkinson-White syndrome is a congenital heart disease characterized by an accessory atrioventricular connection distinct from the AV node-His bundle system. It is associated with AV reentrant tachycardia and/or atrial fibrillation with fast ventricular responses via the accessory pathway. The current surgical management is ablation of the accessory pathway using either an endocardial dissection or epicardial approach. Surgical ablation is associated with high efficacy and low morbidity. Epicardial dissection of the accessory pathway on the beating heart has helped to localize variant accessory pathways associated with Coumel's tachycardia or Mahaim's fiber electrophysiological entity. AV nodal reentrant tachycardia can be cured using direct AV nodal dissection (or perinodal cryoablation). Atrial flutter can be interrupted by cryoablation of the arrhythmogenic substrate located in the coronary sinus orifice of the region modifying atrial inputs. Chronotropic atrial function abolished by chronic or paroxysmal idiopathic atrial fibrillation can be restored using the corridor operation (sinus node-AV node insulation). Surgery is an alternative in patients with resistant atrial tachycardias. Currently surgery is indicated only after other non-invasive EP interventions have been either attempted or rejected.
 ...
PMID:Surgery for supraventricular tachyarrhythmias. 176 6

Fifty patients with supraventricular tachycardia (SVT) underwent clinical electrophysiological studies (EPS), endomyocardial biopsies and cardiac catheterizations. EPS revealed AV nodal reentrant tachycardia (AVNRT) in seven patients, AV reentrant tachycardia utilizing concealed AV bypass tracts (AVR-CBT) in nine patients, AV reentrant tachycardia utilizing AV bypass tracts with ventricular preexcitation (manifest WPW) in 13 patients, sinus nodal or intra-atrial reentrant tachycardia (SNRT or IART) in three patients, atrial flutter (AF) in nine patients, automatic atrial tachycardia (AAT) in five patients, and multifocal atrial tachycardia (MAT) in four patients. According to the clinical observations, three patients with AVNRT (43%), six with AVR-CBT (67%), six with manifest WPW (46%), two with SNRT or IART (67%), eight with AF (89%), two with AAT (40%), and two with MAT (50%) showed other accompanying clinical abnormalities. In all patients who were studied histologically, changes in the myocardium were seen; myocarditic changes, postmyocarditic changes and nonspecific abnormalities were present in six (12%), 15 (30%), and nine (18%) respectively. Myocardial changes were observed in four out of seven cases with AVNRT (57%), in six out of nine with AVR-CBT (67%), in five out of 13 with manifest WPW (38%), in two out of three with SNRT or IART (67%), in six out of nine with AF (67%), in all five cases of AAT (100%), and in two out of four with MAT (50%). Nineteen out of 32 without clinical abnormalities except for arrhythmias (59%) had myocardial changes (six had myocarditic changes, ten had postmyocarditic changes, and three had nonspecific abnormalities). On the other hand, nine out of 21 with myocarditic or postmyocarditic changes were accompanied with various arrhythmias other than SVT (two had SSS, five had AV block or rBBB, and two had VT). Elevated LVEDP was present in 36% of the group with normal myocardium and in 53% of the group with myocardial changes. However, the low EF was shown in no patients with normal myocardium but in 21% of the group with myocardial changes. The low CI was also shown in only 9% of the group with normal myocardium but in 28% of the group with myocardial changes. These results suggest that patients with SVT may exhibit several histopathological changes in the myocardium, even in the absence of any clinical organic heart disease.
 ...
PMID:Clinical, electrophysiological, and histopathological observations in supraventricular tachycardia. 245 68

The clinical, electrocardiographic and electrophysiologic determinants and effects of antiarrhythmic agents on sustained sinus node reentrant tachycardia remain poorly defined. Of 65 consecutive men undergoing electrophysiologic studies for symptomatic paroxysmal supraventricular tachycardia over a 4 year period, 11 (16.9%), who ranged in age from 39 to 76 years, demonstrated sustained sinus node reentrant tachycardia. On the surface electrocardiogram, before electrophysiologic studies, the following diagnoses were considered in the 11 patients: sinus node reentrant tachycardia on the basis of an RP'/P'R ratio of greater than 1 and P wave configuration similar to that of sinus P waves (7 patients); atrioventricular (AV) nodal reentrant tachycardia on the basis of an RP'/P'R ratio of less than 1 (3 patients); and paroxysmal atrial tachycardia with AV block (1 patient). All 11 patients had a history of recurrent palpitation, 4 had syncope, 2 had dizzy spells and 9 had organic heart disease. Sustained sinus node reentrant tachycardia could be reproducibly induced in all 11 patients during atrial pacing or premature atrial stimulation, or both, over a wide echo zone. The tachycardia could be terminated by carotid sinus massage, atrial pacing and premature atrial stimulation. Characteristics of tachycardia included: high-low activation sequence; cycle lengths of 250 to 590 ms with wide fluctuations of 20 to 180 ms in individual patients; RP'/P'R ratio of greater than 1 in 8 (73%) of the 11 patients and a ratio of less than 1 in 3 (27%). Induction of sustained sinus node reentrant tachycardia was prevented by intravenous ouabain (0.01 mg/kg body weight) in two of two patients, by intravenous verapamil (10 mg) in two of two patients and by intravenous amiodarone (5 mg/kg body weight) in four of four patients. In contrast, intravenous propranolol (0.1 mg/kg body weight) did not affect induction of sustained sinus node reentrant tachycardia in two of two patients. It is concluded that sustained sinus node reentrant tachycardia, seen in 16.9% of the study patients with paroxysmal supraventricular tachycardia, is not as benign as previously believed; it is frequently associated with organic heart disease; it demonstrates wide variations in cycle length, unlike other forms of paroxysmal supraventricular tachycardia; it can masquerade as AV nodal reentrant tachycardia and paroxysmal atrial tachycardia with AV block on the surface electrocardiogram in 36% of patients; and it is responsive to intravenous administration of ouabain, verapamil or amiodarone.
 ...
PMID:Sustained symptomatic sinus node reentrant tachycardia: incidence, clinical significance, electrophysiologic observations and the effects of antiarrhythmic agents. 396 8

Radiofrequency catheter ablation was performed in 21 patients who had congenital heart diseases associated with accessory pathway (AP)-mediated tachycardia (14 patients), with atrioventricular (AV) nodal reentrant tachycardia (4 patients), with intraatrial reentrant tachycardia (1 patient), with coexistent AP mediated tachycardia and AV nodal reentrant tachycardia (1 patient) and with coexistent AV nodal reentrant tachycardia and atrial tachycardia (1 patient). Congenital heart diseases diagnosed were seven with Ebstein's anomaly and six with septal defect; the others included patent ductus arteriosus, supravalvular aortic stenosis and left superior vena cava-coronary sinus fistula. Incidence of multiple APs (26.7 vs. 7.7%, P = 0.027), antidromic tachycardia (20.0 vs. 2.9%, P = 0.011), tachyarrhythmia-related syncope (26.7 vs. 7.2%, P = 0.022) and cardiac arrest (13.3 vs. 0%, P = 0.001) was higher in patients with AP and congenital heart diseases. Longer procedure (3.9 +/- 0.7 vs. 2.4 +/- 1.3 h for AP, P = 0.001; 3.0 +/- 0.7 vs. 2.5 +/- 0.8 h for AV nodal reentrant tachycardia, P = 0.001), and radiation exposure times (102 +/- 27 vs. 35 +/- 23 min for AP, P = 0.001; 62 +/- 23 vs. 20 +/- 11 min for AV nodal reentrant tachycardia, P = 0.001) were necessary to achieve a high success rate (95%) in patients with congenital heart disease.
 ...
PMID:Radiofrequency catheter ablation of paroxysmal supraventricular tachycardia in patients with congenital heart disease. 759 25

Our purpose was to assess the efficacy and safety of intravenous ATP for the acute termination of paroxysmal supraventricular tachycardia. There were 14 women and 10 men, aged 38 +/- 15 years. Three patients had evidence of structural heart disease (Ebstein's anomaly associated to atrial septal defect, operated mitral stenosis with insertion of a mechanical heart valve and CAD respectively). Twelve patients had Wolff-Parkinson-White syndrome and another had undergone surgical ablation of an accessory pathway. At the time of electrophysiologic testing, ATP was administered during episodes of paroxysmal supraventricular tachycardia, via a central vein, in incremental doses of 5, 10 and 20 mg followed by a flush of 10 c.c. of isotonic saline. The mechanism of the arrhythmia was orthodromic AV reentrant tachycardia in 19 (79%), AV nodal reentrant tachycardia in 4 (16.6%) and atrial tachycardia in one patient. The mean frequency of the tachycardia was 174 +/- 33 b.p.m. A dose of 5 mg was effective in 16 patients (66%), 5 required 10 mg and two required 20 mg for termination of the tachycardia. In the patient with atrial tachycardia ATP was not effective. The average time after injection to termination of the arrhythmia was 16 +/- 8 seconds. Orthodromic AV reentrant tachycardia was interrupted in the AV node limb in all but one patient and AV nodal reentry was terminated in the "slow-pathway" in three of the four patients. Nine patients had premature ventricular complexes, isolated or in couplets, after the termination of the SVT. Three patients had immediate recurrence of the SVT.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Efficacy and safety of adenosine triphosphate in the control of supraventricular paroxysmal tachycardia]. 804 86

Supraventricular tachycardia (SVT) is the most common sustained arrhythmia to present in the neonatal and infancy age group. Predisposing factors (congenital heart disease, drug administration, illness and fever) occur only in 15% of infants. The presentation of SVT in the neonate is frequently subtle, and may include pallor, cyanosis, restlessness, irritability, feeding difficulty, tachypnea, diaphoresis and grunting. Congestive heart failure is more common in infants under 4 months of age (35% incidence). Age-related differences in the distribution of SVT mechanisms occur in different age groups. In infants under 1 year of age, the mechanisms underlying SVT are atrial tachycardia (15%), AV nodal re-entry tachycardia (5%), and AV reciprocating tachycardia (80%). Options for acute management include: use of the diving reflex, intravenous adenosine, transesophageal pacing, and cardioversion. Intravenous administration of verapamil should be avoided. Data regarding freedom from recurrence of untreated SVT in the first year of life are limited, and may be in the range of 25-60%. Chronic therapy with digoxin, beta-blockers, flecainide, sotalol and amiodarone has proved effective in controlling recurrent episodes of SVT. Radiofrequency ablation can be employed successfully in medically refractory cases, but should be avoided in this age group (increased complication rate).
 ...
PMID:Supraventricular tachycardia in the neonate and infant. 1082 87

The clinical introduction of catheter ablation in 1981 revolutionized the treatment of cardiac arrhythmias. Implementation of radiofrequency as an alternative energy source, with the advantages of higher selectivity and less collateral damage, provided an expansion of catheter ablation therapy. Today the majority of arrhythmias can potentially be cured with catheter ablation therapy. The safety and efficacy of catheter ablation for treatment of AV nodal reentrant tachycardia, accessory pathway arrhythmias, focal atrial tachycardia, atrial flutter and idiopathic ventricular tachycardia, is well established. Catheter ablation for treatment of atrial fibrillation and ventricular tachycardia secondary to structural heart disease, remains an area of active research. In this article we will review the current state of knowledge about the technique, indications, and results of catheter ablation for the treatment of cardiac arrhythmias.
 ...
PMID:Catheter ablation for cardiac arrhythmias. 1210

OBJECTIVE: To investigate the correlation between RFCA catheter cumulative energy and autonomic nerve injury. METHODS: Forty-one patients with paroxysmal supraventricular tachycardia were enrolled, Patients were excluded if they had Diabetes, Hypertension, Congestive Heart Failure or other organic heart disease. HRV and biochemical markers were measured before and after the RFCA. RESULTS: Compared with pre-ablation values,there was significantly decrease in post-ablation low frequency (LF) and high frequency (HF). This was noted in both the septal group (AVNRT and septal pathway) and free wall group (free wall accessory pathway).Post-procedure,the sensitivity of cardiac troponin I(cTnI) for myocardial injury detection was 58.3%, AST was 41.7%. This was significantly higher than other markers(CK:4.2%, CK-MB:10.4%, LDH:20.8%). The post-ablation sensitivity of cTnI was 54.2%, 6.3% and 52.1%at 1 hour, 12 hours, and 24 hours respectively. A significant correlation between cumulative energy and delta HF(r=0.688,P=0.01) or delta LF (r=0.462, P<0.05).was noted in free wall group.(delta HF=pre-ablation HF-post-ablation HF/pre-ablation HF x 100%). There was no significant correlation between biochemical markers and either delta HF or delta LF. CONCLUSION: RFCA induced injury on cardiac autonomic nerves related to both cumulative energy and ablation site,but not size of myocardial injury as determined by cTnI measurement. cTnI is an excellent biochemical marker of myocardial injury.
 ...
PMID:[Radiofrequency catheter ablation autonomic nerve injury] 1259 13

Atrioventricular nodal reentrant tachycardia is the most frequent regular supraventricular tachycardia. It is generally a benign arrhythmia and usually it is no associated with heart disease. It is more often seen in middle-aged women but it is no infrequent in younger and older patients. The development of radiofrequency with catheter ablation has provided the possibility to definitely cure the arrhythmia and moreover permit a better comprehension of the underlying electrophysiologic and anatomic substrate.
 ...
PMID:[Atrioventricular nodal reentrant tachycardia: Radiofrequency ablation]. 1289 92


1 2 Next >>